Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections
Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections
复制标题
DOI：
10.1093/jac/dkh546
复制
发表时间：
2005-03-01
影响因子：
5.2
通讯作者：
Tally, FP
中科院分区：
文献类型：
--
作者：
Steenbergen, JN;Alder, J;Tally, FP
耐药病原体引起的感染呈上升趋势。达托霉素是一种环脂肽，具有抗大多数革兰氏阳性病原体的活性，包括万古霉素耐药肠球菌和耐甲氧西林金黄色葡萄球菌，是美国fda新近批准的用于复杂皮肤和皮肤结构感染（cSSSI）的抗菌药物。达托霉素具有破坏膜电位的独特作用机制。达托霉素的快速杀菌活性使其成为治疗严重革兰氏阳性感染的有吸引力的抗生素。
Infections caused by drug-resistant pathogens are on the rise. Daptomycin, a cyclic lipopeptide with activity against most Gram-positive pathogens, including vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus, is a newly US-FDA approved antimicrobial for complicated skin and skin structure infections (cSSSI). Daptomycin has a unique mechanism of action that results in destruction of the membrane potential. The rapid bactericidal activity of daptomycin makes it an attractive antibiotic for serious Gram-positive infections.